Validation Study for Non-Invasive Prediction of IDH Mutation Status in Patients with Glioma Using In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning

URN to cite this document:: urn:nbn:de:bvb:355-epub-524407
DOI to cite this document:: 10.5283/epub.52440

Bumes, Elisabeth

; Fellner, Claudia ; Fellner, Franz A. ; Fleischanderl, Karin ; Häckl, Martina ; Lenz, Stefan ; Linker, Ralf A.

; Mirus, Tim ; Oefner, Peter J.

; Paar, Christian ; Proescholdt, Martin A.

; Riemenschneider, Markus J.

; Rosengarth, Katharina ; Weis, Serge ; Wendl, Christina ; Wimmer, Sibylle ; Hau, Peter

; Gronwald, Wolfram

; Hutterer, Markus

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 22 Jun 2022 07:06

Alternative links to fulltext:DOI Pubmed Publisher Publisher

Details

Preview

Export bibliographical data

Abstract

The isocitrate dehydrogenase (IDH) mutation status is an indispensable prerequisite for diagnosis of glioma (astrocytoma and oligodendroglioma) according to the WHO classification of brain tumors 2021 and is a potential therapeutic target. Usually, immunohistochemistry followed by sequencing of tumor tissue is performed for this purpose. In clinical routine, however, non-invasive determination of ...